Researchers Look for Novel Immunomodulating Targets with Potential to Transform Glioblastoma Treatment
Glioblastoma remains one of the most debilitating and difficult-to-treat types of brain cancer. This type of cancer originates from the supportive tissue of nerve cells in the brain and spinal cord before very quickly invading and damaging healthy brain tissue. The speed with which glioblastomas proliferate, their proximity to crucial brain tissue and their potent immune-suppression abilities make treating glioblastomas incredibly difficult and often result in low survival outcomes for patients once they are diagnosed. With a five-year survival rate of only 6.9% and an average postdiagnosis survival rate of around eight months, glioblastoma takes more than 100,000 lives in…











